Comparing Levetiracetam and phenobarbital as first-line treatment for neonatal seizures

Comparing the therapeutic efficacy of intravenous Levetiracetam and phenobarbital as first-line treatment for neonatal seizures

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220410054471N1

Enrollment

Registered

2023-07-26

Start date

2019-03-21

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal seizure. Convulsions of newborn

Interventions

Intervention 1: Intervention group: Bolus Intravenous Levetiracetam (Matever) with a 20 mg/kg dose as initial therapy. Intervention 2: Control group: Bolus Intravenous phenobarbital with a 20 mg/kg d

Eligibility

Sex/Gender

All

Age

No minimum to 28 Days

Inclusion criteria

Inclusion criteria: Neonates with seizure manifestations

Exclusion criteria

Exclusion criteria: Renal impairment Lack of consent

Design outcomes

Primary

Measure	Time frame
Seizure control. Timepoint: 48 hours. Method of measurement: clinical.;Seizure recurrence control. Timepoint: 48 hours. Method of measurement: Clinical.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKamyar Kamrani

Tehran University of Medical Sciences

K_kamrani@sina.tums.ac.ir+98 21 7301 3000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026